Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb;17(1):8-15.
doi: 10.1007/s11914-019-00502-4.

Stopping Denosumab

Olivier Lamy  1   2 , Delphine Stoll  3 , Bérengère Aubry-Rozier  3   4 , Elena Gonzalez Rodriguez  3   5
Affiliations
Review

Stopping Denosumab

Olivier Lamy et al. Curr Osteoporos Rep. 2019 Feb.

Erratum in

  • Correction to: Stopping Denosumab.
    Lamy O, Stoll D, Aubry-Rozier B, Gonzalez Rodriguez E. Lamy O, et al. Curr Osteoporos Rep. 2022 Oct;20(5):363. doi: 10.1007/s11914-020-00565-8. Curr Osteoporos Rep. 2022. PMID: 32006208 No abstract available.

Abstract

Purpose of review: Denosumab discontinuation is associated with a rebound effect manifesting by an increased risk of multiple spontaneous vertebral fractures. The purpose of this review is to (1) better characterize this risk and (2) find solutions to avoid it.

Recent findings: In the absence of a potent bisphosphonate prescription at denosumab discontinuation, the frequency of multiple vertebral fractures is common or frequent (≥ 1/100 and < 1/10). In five recent case series, the median number of vertebral fractures was 5 within 7 to 20 months (median 11) after the last denosumab injection. Prescribing bisphosphonate before starting denosumab and/or after stopping denosumab may reduce this risk. However, only small case series have evaluated these strategies. After the second denosumab dose, there is a rebound effect with an increased risk of multiple vertebral fractures. A potent bisphosphonate prescribed at denosumab discontinuation could reduce this risk. As denosumab discontinuation is characterized by many uncertainties, denosumab is a second-line treatment for osteoporosis. Studies are urgently needed to define the management of denosumab discontinuation.

Keywords: Denosumab discontinuation; Osteoporosis; Rebound effect; Spontaneous multiple vertebral fractures.

PubMed Disclaimer

References

    1. Osteoporos Int. 2017 Apr;28(4):1355-1363 - PubMed
    1. Joint Bone Spine. 2018 Oct;85(5):515-517 - PubMed
    1. Osteoporos Int. 2016 May;27(5):1917-21 - PubMed
    1. Bone. 2017 May;98:54-58 - PubMed
    1. N Engl J Med. 2006 Feb 23;354(8):821-31 - PubMed

MeSH terms